Developing A Better Test For Lyme Disease Diagnosis (and more evidence of persistent infection after antibiotic treatment) Dr. Eric Kaldjian, CMO of RareCyte, is the Principal Investigator on the grant. In a preliminary pilot study, the team, which also includes Dr. Denise McKibben and Donna Guralski at WCHN and Dr. Joshua Nordberg of RareCyte, analyzed blood samples of a small cohort of patients clinically diagnosed with acute Lyme disease using RareCyte technology before, during and after antibiotic treatment. In all patients, B.burgdorferi-positive staining objects were identified in the blood. In some cases the positive staining objects persisted even after antibiotic treatment had been completed. Based on these preliminary results, we see a potential for monitoring symptomatic patients for response to antibiotic therapy as well. However, the RareCyte assay for Lyme disease detection requires further development and study before it can be made available for routine clinical use. The SBIR grant will support that effort, said Dr. Kaldjian. Lyme disease research advocate, Senator Richard Blumenthal states, The lack of advanced diagnostic technology and adequate information about this pernicious disease means Lyme all too often goes undetected in its victims, ultimately causing lasting and devastating harm. This grant will fund important strides in understanding Lyme disease, helping lead to earlier detection and better treatment of the illness. The Western Connecticut Biomedical Institute is a trailblazer in this effort. Their research will further efforts to better understand the effects of this epidemic and the best ways in which we can protect ourselves from it. danburyhospital.org/en/News-and-Health-Alerts/2014/August/Developing-a-Better-Test-for-Lyme-Disease
Posted on: Thu, 07 Aug 2014 18:24:45 +0000
Trending Topics
Recently Viewed Topics
© 2015